A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA
I4V-MC-JAIV - ClinicalTrials.gov - NCT03742973
This study evaluates the safety and efficacy of baricitinib in participants with primary biliary cholangitis (PBC) who do not respond or are unable to take ursodeoxycholic acid (UDCA).
Trial Summary
Age Range
≥18 yearsConditions the trial is for
What the trial is testing?
Could I receive a Placebo?
YesEnrollment Goal
2Trial Dates
Mar 28, 2019 - Sep 26, 2019How long will I be in the trial?
The study will last about 16 weeks and may include up to 7 visits.Trial Phase
IILilly Trial Alerts
Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
You will complete the questionnaire on another website.YesNo